INTS (Intensity Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Intensity Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-2.67 Mil. Intensity Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Intensity Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Intensity Therapeutics's current FCF Yield % is -50.13%.

The historical rank and industry rank for Intensity Therapeutics's FCF Margin % or its related term are showing as below:

INTS's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -131.635
* Ranked among companies with meaningful FCF Margin % only.

Intensity Therapeutics FCF Margin % Historical Data

The historical data trend for Intensity Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics FCF Margin % Chart

Intensity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

Intensity Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Intensity Therapeutics's FCF Margin %

For the Biotechnology subindustry, Intensity Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intensity Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Intensity Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Intensity Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-15.22	/	0
	=	%

Intensity Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.668	/	0
	=	%

Intensity Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intensity Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779

Website

https://www.intensitytherapeutics.com

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Executives

Emer Leahy	director	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers	officer: Executive VP of CF	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender	director, 10 percent owner, officer: President and CEO	765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg	director	PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski	officer: Interim CFO	61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880